Select Page

Emerging Trends in Ophthalmic Biosimilars Policy in Canada – 2022 Roundtable

Biosimilars Policy in Canada 2022 banner

Over 2 million Canadians are currently living with vision loss as a result of retinal diseases.  The current most advanced treatments available for eye conditions include biologic anti-VEGF treatment as a way to slow vision loss in people with wet age-related macular degeneration (wAMD) or diabetic retinopathy (DR).  However, with patents on the anti-VEGF biologics soon to expire, there is an emerging trend toward the use of biosimilars in ophthalmic practice.  Government policies in India, Europe, and the United States of America (USA) to procure and implement biosimilars are not only about the safety and efficacy of the regimen, but also the potential cost-savings.

In Canada, various federal and provincial consultations have informed the broad landscape of biosimilars policies, yet sparse attention has been given to specific fields such as ophthalmology.  Awareness and education of biosimilars (rather than the originator) as a treatment option is an important step towards the development of policies that support safe and effective management and treatment, specific to the needs of patients and their medical conditions.

 

 

The Findings

 

To position this emerging field in a Canadian context with a focus on awareness and education of physician and patients, and the barriers of implementing biosimilar policies globally, the International Federation on Ageing (IFA) convened a virtual roundtable discussion on Emerging Trends in Ophthalmic Biosimilars Policy in Canada’.  Leaders of civil society and patient advocacy groups, alongside retinal specialists and public policy experts shared perspectives in this forum on biosimilar policies and practice with respect to the changing vision health landscape in Canada.

The meeting unpacked details related to physician and patient experiences and the level of awareness of biosimilars, along with the challenges and successes of implementing biosimilars policies globally, and the potential impact of mandatory non-medical switching to biosimilars policies on patients in Canada.

Emerging Trends in Ophthalmic Biosimilars in Canada - Roundtable Summary Report coverEmerging Trends in Ophthalmic Biosimilars Policy in Canada

Roundtable Summary Report

International Federation on Ageing

DOWNLOAD HERE

Analysis of Biosimilars Policies the European, American, and Canadian Landscape - ASBMAnalysis of Biosimilars Policies

The European, American, and Canadian Landscape

Michael Reilly | Executive Director, ASBM

DOWNLOAD HERE

Comparison of Global Biosimilar - Biosimilars ForumComparison of Global Biosimilar Policies

A Closer loot at safety, efficacy and regulation

Biosimilars Forum

DOWNLOAD HERE

Global Perspective on Biosimilar Markets and Sustainability - IQVIAGlobal Perspective on Biosimilar Markets and Sustainability

International Federation on Ageing Roundtable

IQVIA Institute

DOWNLOAD HERE

Patient and Physician Experience with Ophthalmic Biosimilars from India - Lotus Eye Hospital and InstitutePatient and Physician Experience with Ophthalmic Biosimilars from India

The Indian Experience

Dr. Ashish Sharma | Lotus Eye Hospital and Institute

DOWNLOAD HERE

Emerging Trends in Ophthalmic Biosimilars Policy in Canada – 2022 Roundtable

 

This roundtable is supported by the generous unrestricted educational sponsorship from Biogen

Social Media Kit

 

The IFA has created the following Social Media kit to help organizations for older adults share impactful information to their members.

Ophthalmic Biosimilars Policy in Canada - IFA 2022 BannerPost:

#Governments must develop policies that move the biosimilar discussion beyond an economic savings model toward the health and well-being of patients. This begins with interdisciplinary and multi-sectoral collaboration and targeted advocacy efforts. https://bit.ly/3L9E9m5  #ifa #vision #health #biosimilars

Download for Facebook

Ophthalmic Biosimilars Policy in Canada - IFA 2022 BannerPost:

#Governments must develop policies that move the biosimilar discussion beyond an economic savings model toward the health and well-being of patients. This begins with interdisciplinary and multi-sectoral collaboration and targeted advocacy efforts. https://bit.ly/3L9E9m5  #ifa #vision #health #biosimilars

Download for Instagram

Ophthalmic Biosimilars Policy in Canada - IFA 2022 BannerPost:

#Governments must develop policies that move the biosimilar discussion beyond an economic savings model toward the health and well-being of patients. This begins with interdisciplinary and multi-sectoral collaboration and targeted advocacy efforts. https://bit.ly/3L9E9m5  #ifa #vision #health #biosimilars

Download for Twitter

Share This